Table 2.

Subgroup analysis of PFS, OS, ORR, and AEs

	PFS		OS		ORR		AEs (Grade ≥3)
	HR (95% CI)	P-value	HR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value
1. Bevacizumab in the control group was used
Yes	0.76 (0.64, 0.90)	0.001	1.06 (0.86, 1.30)	0.605	1.58 (1.08, 2.30)	0.019	1.46 (0.99, 2.17)	0.058
No	0.53 (0.44, 0.65)	0.000	0.87 (0.71, 1.08)	0.220	4.11 (2.50, 6.78)	0.000	2.68 (1.83, 3.93)	0.000
2. Corticosteroid drug was used, rate (%)
N<50	0.58 (0.49, 0.69)	0.000	0.94 (0.77, 1.14)	0.536	2.08 (0.85, 5.08)	0.108	1.90 (0.82, 4.38)	0.134
N>50	0.79 (0.63, 0.98)	0.029	0.99 (0.83, 1.12)	0.921	1.92 (1.13, 3.27)	0.016	1.69 (1.10, 2.60)	0.017

Abbreviations: PFS, progression-free survival; OS, overall survival; ORR, object response rate; AEs, adverse events.